Agilon Health Inc. (NYSE:AGL) shares are soaring on Thursday as the company recently announced an increase in its full-year 2026 guidance. The company operates and manages a network of independent physicians.
Agilon Health Shares Rise After Guidance Increase
The company announced results that reflect disciplined execution and progress against its strategic priorities.
Agilon Health reported first-quarter earnings of $1.80 per share, beating the consensus of $1.31.
Sales reached $1.42 billion, surpassing the Wall Street estimate of $1.38 billion.
Revenues fell 7% year over year, reflecting lower year-over-year membership partially offset by improved pricing, contract economics, and burden of illness performance.
Membership Declines While Margins Improve
Total members on the Agilon platform decreased to 536,000 as of March 31, 2026, including 426,000 Medicare Advantage members and 110,000 ACO model beneficiaries.
Medical margin was $149 million, up from $128 million a year ago. Medical margin includes the cost trend for Medicare Advantage members reserved at 7.4%.
Adjusted EBITDA was $54 million, up from $21 million a year ago.
We are seeing early returns from investments in data and technology, clinical execution, and operating discipline,” said Ronald Williams, Executive Chairman.
Agilon Health Raises 2026 Revenue Outlook
“We are also strengthening our Total Care Model—expanding clinical pathways, improving quality, and deepening payor alignment—positioning us for more predictable outcomes and sustained margin expansion. We remain confident in our 2026 outlook and long-term growth trajectory,” Williams further added.
Agilon Health expects second-quarter sales of $1.44 billion-$1.48 billion compared to the consensus of $1.34 billion.
The company raised its fiscal 2026 sales guidance from $5.41 billion-$5.58 billion to $5.68 billion-$5.81 billion, versus the consensus of $5.45 billion.
William Blair notes it was a good start to 2026, and ongoing clinical, cost-cutting, and operational initiatives appear to be driving a solid turnaround at the company.
How Agilon Health (AGL) Ranks On Momentum
Below is the Benzinga Edge scorecard for Agilon Health, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Neutral (Score: 58.56) — Stock is showing moderate performance indicators.
The Verdict: Agilon Health’s Benzinga Edge signal reveals a momentum-driven story, suggesting that while the stock has shown some recovery, it remains to be seen if this upward trend can be sustained in the long term.
AGL Price Action: Agilon Health shares were up 99.89% at $55.67 at the time of publication on Thursday, according to Benzinga Pro data.
Image via Shutterstock
Login to comment